What is the current price and intraday volume for 4564.T stock?

As of this intraday report on 18 Feb 2026, 4564.T stock trades at **JPY 21.00** with **24,107,900** shares traded today, versus an average volume of **47,144,176**.

What does Meyka AI forecast for 4564.T price this year?

Meyka AI's model projects a yearly target of **JPY 18.02**, implying about **-14.14%** from the current **JPY 21.00**. These model forecasts are projections and not guarantees.

What are the main risks for OncoTherapy Science investors?

Primary risks include negative earnings, clinical trial setbacks, possible dilution from fundraising, and valuation compression. Balance-sheet strength reduces short-term solvency risk but not trial outcome risk.

How does OncoTherapy Science compare to the Healthcare sector?

The Healthcare sector average PE is **22.91** and average ROE is **12.00%**. OncoTherapy has negative earnings and a negative PE, so it trades more like a clinical-stage biotech than a mature pharma.

JP Stocks

4564.T OncoTherapy Science JPX JPY 21.00 intraday 18 Feb 2026: active trading interest

ByHuzaifa Zahoor February 18, 2026

4564.T stock is trading at JPY 21.00 on the JPX intraday tape on 18 Feb 2026, with 24,107,900 shares changing hands so far. The biotech OncoTherapy Science, Inc. (4564.T) shows a day range JPY 20.00–21.00, a 52-week range of JPY 19.00–35.00, and a market cap near JPY 7,216,515,579. Volume places the name among today’s most active issues, making short-term liquidity and re-rating risk key for traders and investors watching clinical milestones and sector moves in Healthcare.